Use of recombinant factor VII in hepatology.
Understanding the key role of factor VII (FVII) in the cascade of blood coagulation has led to consider its administration as an effective treatment for selected situations with altered haemostasis. Advances in genetic engineering have made it possible to obtain this factor by recombinant techniques (rFVII), rendering it both safe and widely available as a haemostatic treatment. So far, it has been commonly used for haemophilic patients with inhibiting antibodies against factors FVIII-FIX, but its use is currently extending to other areas. The presence of decreased FVII levels in patients with advanced, chronic liver disease has recently raised an interest in the study of this molecule as a new therapeutic option in the field of Hepatology. This paper will discuss the characteristics, indications, and studies existing to this day on the use of rFVII, particularly in cirrhotic patients.
Romero Castro
R
R
Gastroenterology Department, Virgen Macarena University Hospital, Seville, Spain.
Barroso Relinque
N
N
Caunedo Alvarez
A
A
García Montes
J M
JM
Herrerías Gutiérrez
J M
JM
D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000209:etiology; D005167:Factor VII / Q000627:therapeutic use*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D005167:Factor VII